Treace Q2 2026 revenue $45.4M (-4% YoY), net loss $15.9M, raises FY guidance

TREACE MEDICAL CONCEPTS, INC.

2026-Q2 EPS reported -$0.52 revenue$92,574,000

Q2 2026 revenue $45.4M vs $47.4M in Q2 2025 (-4%); net loss $(15.9)M or $(0.24)/share.
Adjusted EBITDA loss $(3.5)M, improved from $(3.6)M; gross margin 78.5% vs 79.7%.
Cash usage cut 57% YoY; cash and securities $45.6M at June 30, 2026.
FY 2026 revenue guidance raised to $204-212M (from $202-212M); EBITDA loss narrowed to $3-5M.
New products: SuperBite Screw System launched, HyperPlate XM first case; 40% of surgeons use new bunion systems.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.